QuantLogix ← DXCM scorecard
📅 DXCM Earnings Preview
DexCom, Inc.
Next report (est.)
01/07/2027
Countdown
117 days
EPS growth YoY
+42.2%
Revenue growth YoY
+13.1%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
07/30/2026 ±3.1% -0.8% over-priced
10/30/2025 ±3.0% +0.0% over-priced
07/30/2025 ±1.6% -0.3% over-priced
05/01/2025 ±3.1% -1.6% over-priced
10/24/2024 ±2.4% +3.3% under-priced
07/25/2024 ±2.9% -3.6% under-priced
04/25/2024 ±3.1% +0.1% over-priced
10/26/2023 ±3.1% -3.9% under-priced
Across these reports, options implied an average ±2.8% move vs an actual average of 1.7% — the stock stayed inside the implied band 63% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $0.64 $1.3B $249M
Q1 FY2026 $0.51 $1.2B $200M
Q4 FY2025 $0.67 $1.3B $267M
Q3 FY2025 $0.70 $1.2B $284M
Analyst posture
Buy / Strong Buy
31
Hold
5
Sell
0
Stable: +0 net change 30d
Live 5-factor engine read: Buy · 65/100 Full scorecard →
Get alerted before every DXCM report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on DXCM before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

DexCom, Inc. (DXCM) reports in 117 days, with the next report estimated for 01/07/2027. Across the last 8 reports, options priced an average ±2.8% earnings move while the stock actually moved 1.7% on average — the market has been roughly fair on DXCM's earnings risk. Fundamentals into the print: EPS up 42.2% year-over-year, revenue up 13.1%. QuantLogix's live 5-factor engine currently reads DXCM as a buy at 65/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →